Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic reported Q2 fiscal 2022 revenue of $1.436 billion, a 6.6% decline compared to the previous year, primarily due to lower COVID-19 assay sales. However, this figure exceeded the company's guidance of $1.25 to $1.3 billion. GAAP diluted EPS was $1.80, down 24.4% year-over-year, with non-GAAP diluted EPS at $2.07. Despite declines in various segments, the company raised its full-year revenue and EPS guidance, reflecting strong cash flow from operations of $1.062 billion and a robust balance sheet.
Hologic announces that the American Society of Clinical Oncology (ASCO) has updated its guidelines to include Breast Cancer Index™ (BCI) as the only genomic test for determining extended endocrine therapy in early-stage, HR+ breast cancer patients. This guideline aims to help healthcare providers make informed treatment decisions after five years of primary therapy. BCI is recognized for its ability to predict which patients may benefit from continued treatment, mitigating unnecessary side effects associated with extended therapy.
Hologic, Inc. (Nasdaq: HOLX) has announced the release of its second-quarter fiscal 2022 financial results, scheduled for April 27, after market close. A conference call will follow at 4:30 p.m. Eastern Time for discussion of the results. Participants can join by dialing specific numbers or click here to join. A replay will be available post-call until May 27, 2022.
Hologic, Inc. (NASDAQ: HOLX) has launched a new Innovation Center in Aix-en-Provence, France, marking a significant expansion of its commitment to women's health. This facility, which serves as the new French headquarters, will focus on ultrasound, interventional, and surgical solutions in breast health care. Following the acquisition of SuperSonic Imagine in 2019, Hologic aims to enhance access to innovative healthcare technologies in the EMEA region. The investment reflects Hologic's mission to improve the health of 3.9 billion women worldwide.
Hologic has partnered with the WTA to enhance women’s health and wellness through advanced screening technologies, starting at the BNP Paribas Open in Indian Wells. The collaboration includes providing athletes with access to Hologic’s Horizon® DXA system for detailed body composition and bone health analysis. Alongside enhanced screenings, Hologic will support the ACEing Cancer program, aimed at raising awareness and funds for women’s cancers. This partnership aims to prioritize women's health and addresses the decline in health screenings due to the COVID pandemic.
Hologic has announced a landmark multi-year partnership with the WTA, becoming the official health partner and global title sponsor of the WTA Tour. This represents the largest global sponsorship in WTA history and marks Hologic’s first worldwide sponsorship. The collaboration aims to promote women’s health and equality through initiatives that emphasize preventive care and healthy living. Hologic, known for its innovations in women’s health, will also support the creation of Hologic WTA Labs, focusing on health innovation for female athletes.
Hologic, Inc. (Nasdaq: HOLX) has announced its upcoming participation in two significant investor conferences. The first is Citi's 2022 Healthcare Services, Medtech, Tools & HCIT Virtual Conference scheduled for February 23 at 1:15 p.m. ET. The second is The Raymond James Institutional Investors Conference on March 8 at 9:50 a.m. ET. Both presentations will be webcast live and available for 30 days on Hologic's investor website.
Hologic focuses on enhancing women's health through early detection and treatment solutions.
Hologic (HOLX) reported Q1 2022 revenue of $1.471 billion, down 8.6% year-over-year, notably exceeding prior guidance of $1.1-$1.15 billion. GAAP diluted EPS was $1.95 while non-GAAP diluted EPS was $2.17, both below last year's figures. Organic revenue grew 9% excluding COVID sales, with Breast Health and GYN Surgical divisions each above 8% growth. The company significantly raised its full-year revenue guidance by $600 million and non-GAAP EPS by $1.35. Cash flow from operations remained robust at $564.2 million.
Hologic (Nasdaq: HOLX) has unveiled its first national direct-to-consumer advertising campaign, launching during the 'Big Game' on NBC on February 13, 2022. The campaign, titled "Her Health is Her Wealth", features Mary J. Blige and aims to promote preventive screenings for women, emphasizing the importance of regular health check-ups that many missed during the COVID-19 pandemic. Research indicates that nearly 50% of women aged 16-54 have not had a health screening in the past year. The campaign will also include digital activations via ScreeningsForHer.com.
Summary not available.